

1 Effect of intravenous lidocaine dose on pain upon awakening in pediatric  
2 tonsillectomy: A randomized trial

3

4

5

6 Yang Hu<sup>#</sup>, Ming-Cheng Du<sup>#</sup>, Yi Chen<sup>#</sup>, Xiang Long, Jing-Jing Jiang, & Yuan Gong<sup>\*</sup>

7

8

9 Institute of Anesthesiology and Critical Care Medicine, China Three Gorges University &  
10 Yichang Central People's Hospital, Yichang City, Hubei Province, China

11

12 \* Corresponding author

13 E-mail: [gy-yc@163.com](mailto:gy-yc@163.com) (YG)

14

15 # Yang Hu, Ming-Cheng Du, and Yi Chen contributed equally to this work.

## 16 **Abstract**

17 We investigated the potential of intravenous lidocaine to reduce pain on awakening in a dose-  
18 dependent manner and aimed to determine the median effective dose of lidocaine in 200  
19 children aged 3–12 years (American Society of Anesthesiologists physical status I–II) who  
20 underwent elective tonsillectomy with or without adenoidectomy at Yichang Central People’s  
21 Hospital. The patients were randomized into four dose groups (A–D: 0.0, 1.0, 1.5, and 2.0  
22 mg/kg, respectively), and they underwent the same anesthetic induction and maintenance  
23 protocols. The primary outcome was pain on awakening, while secondary outcomes included  
24 pain scores at 1, 4, 12, and 24 h after awakening; incidences of laryngospasm, bronchospasm,  
25 or perioperative stridor; and time to extubation. Intraoperative cardiac events were classified  
26 as safety events. Our findings indicated that intravenous lidocaine dose-dependently reduced  
27 pain on awakening, with the median effective dose being 1.75 mg/kg. Significant differences  
28 were observed between groups A and D ( $P \leq 0.001$ ). No incidents of laryngospasm,  
29 bronchospasm, or perioperative stridor were observed. Furthermore, there were significant  
30 between-group differences in time to extubation ( $P \leq 0.05$ ). In conclusion, our study  
31 demonstrated that lidocaine dose-dependently reduced pain on awakening in children  
32 undergoing tonsillectomy with or without adenoidectomy, with no severe adverse events.

33 **Key Words:** lidocaine, pediatric patient, tonsillectomy, pain on awakening

34

## 35 **Introduction**

36 Tonsillectomy, with or without adenoidectomy, is one of the most common surgical  
37 procedures performed in children wherein children receive general anesthesia via a tracheal  
38 tube [1,2]. Although this surgery is a common and safe procedure in children, severe pain on  
39 awakening is frequently observed following pediatric adenotonsillectomy [3]. It can easily  
40 turn into persistent pain without appropriate treatment and drastically limits patients' oral  
41 intake of fluids and pain medication, potentially extending postoperative length of stay [4,5].

42 Lidocaine is a local anesthetic that is used as a general anesthetic adjunct because of its  
43 analgesic, anti-hyperalgesic, anti-inflammatory, and immunomodulatory properties related to  
44 stress [6–8]. Intravenous lidocaine reduces pain after elective surgery under general  
45 anesthesia [9]. However, it is unclear whether lidocaine reduces pain on awakening in a dose-  
46 dependent manner, and the median effective dose ( $ED_{50}$ ) of intravenous lidocaine in children  
47 remains unknown.

48 We hypothesized that intravenous lidocaine reduces pain on awakening in a dose-dependent  
49 manner and determined the  $ED_{50}$  of lidocaine in children undergoing tonsillectomy with or  
50 without adenoidectomy. The choice of pain on awakening as the primary outcome was  
51 guided by the need for clinically meaningful outcomes with potential benefits.

## 52 **Materials and methods**

### 53 **Ethical Considerations**

54 All procedures performed in studies involving human participants were in accordance with  
55 the ethical standards of the institutional and/or national research committee and with the 1964

56 Declaration of Helsinki and its later amendments or comparable ethical standards. The study  
57 design was approved by the Institutional Review Board (president, Ke-Jun Yan) of Yichang  
58 Central People’s Hospital (approval number: HEC-KYJJ-2020-038-02; approval date:  
59 September 17, 2021). Written informed consent was obtained from the parents or guardians  
60 of all children enrolled in the study.

## 61 **Study Design**

62 This single-center, parallel-group, double-blind, randomized controlled trial (principal  
63 investigator, Yuan Gong) was registered in the Chinese Clinical Trial Registry  
64 (<http://chictr.org.cn/showproj.aspx?proj=136605>) (registration number: ChiCTR2100053006;  
65 registration date: November 8, 2021). The trial was conducted from December 1, 2021, to  
66 May 30, 2022, at Yichang Central People’s Hospital, Hubei Province, China, in accordance  
67 with the CONSORT guidelines. Patients were randomized to each group in an equal (1:1:1:1)  
68 ratio. Randomization was computer-generated, and each patient was assigned a code.

## 69 **Patients**

70 The inclusion criteria were patients aged 3–12 years (American Society of Anesthesiologists  
71 physical status I–II) who were scheduled for elective tonsillectomy with or without  
72 adenoidectomy. Children were divided into the following four groups, according to the dose  
73 of lidocaine administered: A (0.0 mg/kg), B (1.0 mg/kg), C (1.5 mg/kg), and D (2.0 mg/kg).  
74 The exclusion criteria were chronic cough, a history of steroid or bronchodilator treatment,  
75 reactive airway disease, upper airway infection 2 weeks before the procedure, angiotensin-  
76 converting enzyme inhibitor therapy, gastroesophageal reflux, morbid obesity, known allergy  
77 to any of the study drugs, use of medications or nutraceuticals known to affect blood pressure

78 (BP) and heart rate (HR), surgery lasting > 2 h, unexpected bleeding, and the need for > 2  
79 intubation attempts.

## 80 **Perioperative Anesthetic Care**

81 Preoperatively, all children fasted for 6 h and were restricted from oral intake of clear fluids  
82 for 1 h. The children entered the operating room accompanied by their parents to curb  
83 separation anxiety. Non-invasive BP, HR, and pulse oxygen saturation were measured, and  
84 electrocardiography was performed using a multifunction monitor (GE Healthcare, Chicago,  
85 IL, USA). The width of the BP cuff for each patient was approximately two-thirds of the  
86 length of the upper arm. After stabilization for 5 min, baseline HR, systolic BP, diastolic BP,  
87 and mean arterial pressure values were obtained from the average of three measurements  
88 taken 2 min apart. A 22-gauge intravenous catheter was subsequently inserted into a vein on  
89 the back of the hand.

90 After preoxygenation, the drug of interest (lidocaine [Anhui Changjiang Pharmaceutical Co.  
91 Ltd., Wuhu City, China] or 0.9% saline) was administered intravenously for 3 s. An  
92 anesthetic nurse blinded to the study prepared the drug of interest to be administered through  
93 an infusion pump. General anesthesia was induced 2 min after administration, using the  
94 following induction protocol: sufentanil (0.25 µg/kg [Yichang Renfu Pharmaceutical Co.  
95 Ltd., Yichang City, China]), propofol (2.0 mg/kg [Fresenius Kabi Deutschland GmbH,  
96 Homburg, Germany]), and rocuronium (0.6 mg/kg [Zhejiang Xianju Pharmaceutical Co. Ltd.,  
97 Taizhou City, Zhejiang Province, China]). An anesthetist blinded to the study graded the  
98 cough response during injection. When the eyelash reflex disappeared, the lungs were  
99 ventilated via a face mask with 100% oxygen. A cuffed tracheal tube was used, the size of  
100 which was selected based on a widely used formula  $(3.5 + [\text{age (years)}] / 4)$ . The patient was

101 excluded from the study if any difficulty was encountered while performing face mask  
102 ventilation. Anesthesia was maintained with 2–3% sevoflurane (Maruishi Pharmaceutical Co.  
103 Ltd., Osaka, Japan) and 50% oxygen.

104 At the end of the procedure, sevoflurane was discontinued, and neostigmine (0.04 mg/kg  
105 [Zhejiang Xianju Pharmaceutical Co. Ltd.]) and atropine (0.02 mg/kg [Suicheng  
106 Pharmaceutical Co. Ltd., Xinzheng City, China]) were administered to antagonize any  
107 residual neuromuscular blockade. Following surgery, oral suction was immediately  
108 performed, with the patient still under anesthesia. Extubation was performed while the patient  
109 recovered after confirming an adequate tidal volume, a regular spontaneous respiratory  
110 pattern, and purposeful behavior (eyes opened on request). After extubation, an anesthetist  
111 who was not involved in the study assessed recovery from anesthesia, scored the throat pain,  
112 and graded the cough response. Patients were monitored for  $\geq 5$  min, with 100% oxygen via a  
113 face mask, to allow regular spontaneous respiration. Patients were transferred to a post-  
114 anesthesia care unit (PACU) after extubation. The time to extubation (from sevoflurane  
115 discontinuation to tracheal extubation) was recorded. Electrocardiography, peripheral pulse  
116 oximetry, and non-invasive BP measurements were also performed.

117 Patients were discharged from the PACU when their Steward score was  $> 4$ . Other  
118 postoperative care was performed according to the practices of local clinicians. If the pain  
119 (Face, Legs, Activity, Cry, and Consolability scale [children aged 3–4 years], Wong-Baker  
120 scale [children aged 4–7 years], or visual analog scale [children aged  $\geq 8$  years])<sup>3</sup> score was  $\geq$   
121 3 at rest, the attending PACU nurse administered intravenous propacetamol (30 mg/kg) as  
122 treatment. The use of other medications was restricted.

## 123 **Primary Outcome**

124 The primary outcome was pain on awakening.

## 125 **Secondary Outcomes**

126 The secondary outcomes were pain scores at 1, 4, 12, and 24 h after awakening; incidences of  
127 laryngospasm, bronchospasm, and perioperative stridor; and time to extubation. Safety events  
128 included intraoperative cardiac events (arrhythmia, hypotension [mean arterial pressure < 65  
129 mmHg], hypertension [mean arterial pressure > 90 mmHg]), and rescue treatment.

## 130 **Statistical analyses**

131 The sample size was calculated based on an expected pain on-awakening score difference of  
132 1 (clinical significance), with 80% power ( $\alpha = 0.05$ ,  $\beta = 0.2$ ), which indicated that 50 patients  
133 were required per group. Patient characteristics (including age, height, and weight); pain on  
134 awakening scores; incidences of laryngospasm, bronchospasm, and perioperative stridor;  
135 duration of surgery; and time to extubation were expressed as mean  $\pm$  SD and analyzed using  
136 ANOVA, with a P-value < 0.05 indicating a significant difference. Statistical significance  
137 was set at  $P < 0.01$ . All statistical analyses were conducted using GraphPad Prism (version  
138 8.0.2; GraphPad Software Inc., San Diego, CA, USA).

## 139 **Results**


### 140 **Patients**

141 Between December 1, 2021, and May 30, 2022, 200 patients were enrolled and divided into  
142 four groups based on the dose of lidocaine administered(Fig. 1). There were significant  
143 differences in the time to extubation between groups A and B ( $P = 0.014$ ), A and C ( $P =$   
144  $0.015$ ), and A and D ( $P = 0.017$ ). Patient characteristics and other operative data were not

145 significantly different between the groups (Table 1).

146 **Fig. 1 Flow Diagram**

 **CONSORT**  
TRANSPARENT REPORTING of TRIALS  
**CONSORT 2010 Flow Diagram**



147



148 **Table 1. Patient characteristics and clinical data**

	Group A <sup>a</sup>	Group B <sup>b</sup>	Group C <sup>c</sup>	Group D <sup>d</sup>
	(n = 50)	(n = 50)	(n = 50)	(n = 50)
Age (years)	5.55 ± 2.02	6.02 ± 2.35	5.77 ± 1.91	5.98 ± 1.67
Height (cm)	118.34 ± 14.21	120.60 ± 16.02	117.81 ± 13.65	120.49 ± 12.02
Weight (kg)	22.88 ± 7.60	23.57 ± 8.57	22.57 ± 6.65	25.03 ± 7.22
Body mass index (kg/m <sup>2</sup> )	15.96 ± 2.65	15.75 ± 2.22	16.04 ± 2.27	16.97 ± 2.75
Sex (M/F)	26/21	27/20	29/18	29/18
ASA physical status (I/II)	47/0	47/0	47/0	47/0
Duration of surgery (min)	29.74 ± 11.14	29.40 ± 11.10	29.43 ± 13.68	27.34 ± 11.95
Time of extubation (min)	11.55 ± 3.32	13.72 ± 3.30*	13.70 ± 3.59*	13.68 ± 3.58*
Incidence of laryngospasm	0	0	0	0
Incidence of bronchospasm	0	0	0	0
Incidence of perioperative stridor	0	0	0	0
Tonsillectomy with or without	48/2	50/0	50/0	49/1

adenoidectomy

---

149 <sup>a</sup>Group A = lidocaine (0.0 mg/kg) intravenously

150 <sup>b</sup>Group B = lidocaine (1.0 mg/kg) intravenously

151 <sup>c</sup>Group C = lidocaine (1.5 mg/kg) intravenously

152 <sup>d</sup>Group D = lidocaine (2.0 mg/kg) intravenously

153 Values are expressed as n or mean  $\pm$  SD. \* $P < 0.05$  (compared with Group A). ASA,

154 American Society of Anesthesiologists; F, female; M, male

### 155 **Primary outcomes**

156 The ED<sub>50</sub> of intravenous lidocaine for pain on awakening was 1.75 mg/kg (Fig. 2a). All 50

157 patients in each group were assessed for the primary outcome. The score for pain on

158 awakening was significantly different between the groups, in a dose-dependent manner, with

159 significant differences between groups C and D ( $P = 0.037$ ), A and B ( $P = 0.007$ ), B and D ( $P$


160  $= 0.003$ ), and A and C ( $P \leq 0.001$ ). There was also a significant difference between groups A

161 and D ( $P \leq 0.001$ ) (Fig. 2b).

162 **Fig. 2 Intravenous lidocaine for pain on awakening.** (a) Concentration-response curve. (b)

163 Pain on awakening scores. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ ; \*\*\*\* $P < 0.0001$ . ED<sub>50</sub>,

164 median effective dose.



165

## 166 Secondary outcomes

167 The pain score at 1 h after awakening was significantly different between groups A and B ( $P$

168  $\leq 0.001$ ); A, C, and D ( $P \leq 0.001$ ); and B and D ( $P = 0.010$ ). The pain score at 4 h after

169 awakening was significantly different between groups A and B ( $P \leq 0.001$ ); A, C, and D ( $P \leq$

170  $0.001$ ); and B and D ( $P = 0.015$ ); however, there were no significant differences in the pain

171 scores at 12 and 24 h after awakening (Fig. 3). No cases of laryngospasm, bronchospasm, or


172 perioperative stridor were observed in any group. However, significant differences in the time

173 to extubation were observed between groups A and B ( $P = 0.014$ ), A and C ( $P = 0.015$ ), and

174 A and D ( $P = 0.017$ ) (Table 1). No severe complications, such as arrhythmia, were observed

175 in any group.

176 **Fig. 3 Pain scores at 1, 4, 12, and 24 h after awakening.**



177

## 178 Discussion

179 Tonsillectomy is one of the most painful surgical procedures. The relief of pain after  
180 tonsillectomy remains challenging and controversial. Several interventions have been  
181 recommended to control pain after tonsillectomy in children [10]. Opioids are an important  
182 treatment strategy for postoperative pain. However, there is a tendency to avoid using  
183 narcotics for respiratory depression in children. Large studies of non-steroidal anti-  
184 inflammatory drugs have demonstrated effective pain management [10]. However, their  
185 potential for treatment of more severe bleeding events has been debated.

186 In this trial, intravenous lidocaine resulted in a dose-dependent reduction in pain on  
187 awakening, with an ED<sub>50</sub> of 1.75 mg/kg. Even 1 and 4 h after surgery, there was a  
188 considerable reduction in pain scores for those who received lidocaine compared with those

189 who did not receive lidocaine. Only after 12 h did the pain scores on awakening exhibit no  
190 difference between groups. This seems feasible as the duration of surgery was < 1 h and the  
191 half-life of intravenous lidocaine was approximately 2 h [11]. The exact inhibitory  
192 mechanism of lidocaine is unclear. It may involve its analgesic, anti-hyperalgesic, anti-  
193 inflammatory, and immunomodulatory properties related to stress [6–8].

194 No cases of laryngospasm, bronchospasm, perioperative stridor, or other serious  
195 complications were observed during anesthesia. Intravenous lidocaine appears safe and does  
196 not result in serious adverse events in children. Substantial differences in the time to  
197 extubation were observed between the study (B, C, and D) groups and the control (A) group;  
198 the time in the control group was 2 min longer to meet extubation requirements.

199 This study has several limitations. First, it was a single-center study, which reduced its power  
200 and reliability. Second, we used the sevoflurane concentration in end-expiratory gas to  
201 monitor the depth of anesthesia, potentially leading to an increase in the ED<sub>50</sub>.

## 202 **Conclusion**

203 Intravenous lidocaine reduced pain on awakening in children undergoing tonsillectomy with  
204 or without adenoidectomy in a dose-dependent manner without causing serious adverse  
205 events. The ED<sub>50</sub> of intravenous lidocaine for pain on awakening was 1.75 mg/kg.

## 206 **Acknowledgments**

207 We would like to thank Editage ([www.editage.com](http://www.editage.com)) for English language editing.

## 208 **Conflicts of interest and source of funding**

209 None declared.

## 210 **References**

- 211 1. Lerman J. Pediatric ambulatory anesthesia: an update. *Curr Opin Anaesthesiol*  
212 2019;32:708-713.
- 213 2. Bhattacharyya N, Lin HW. Changes and consistencies in the epidemiology of pediatric  
214 adenotonsillar surgery, 1996–2006. *Otolaryngol Head Neck Surg* 2010;143:680-684.
- 215 3. Muzzi E, Ronfani L, Bossini B, Lezcano C, Orzan E, Barbi E. Effects of intraoperative  
216 auditory stimulation on pain and agitation on awakening after pediatric  
217 adenotonsillectomy: a randomized clinical trial. *JAMA Otolaryngol Head Neck Surg*  
218 2021;147:638-645.
- 219 4. Aldamluji N, Burgess A, Pogatzki-Zahn E, Raeder J, Beloeil H, PROSPECT Working  
220 Group collaborators\*, et al. PROSPECT guideline for tonsillectomy: systematic review  
221 and procedure-specific postoperative pain management recommendations. *Anaesthesia*  
222 2021;76:947-961.
- 223 5. Constant I, Khalfallah SA, Brunaud A, Deramoudt V, Fayoux P, Giovanni A, et al.  
224 How to replace codeine after tonsillectomy in children under 12 years of age?  
225 Guidelines of the French Oto-Rhino-Laryngology–Head and Neck Surgery Society  
226 (SFORL). *Eur Ann Otorhinolaryngol Head Neck Dis* 2014;131:233-238.
- 227 6. Hermanns H, Hollmann MW, Stevens MF, Lirk P, Brandenburger T, Piegeler T, et al.  
228 Molecular mechanisms of action of systemic lidocaine in acute and chronic pain: a  
229 narrative review. *Br J Anaesth* 2019;123:335-349.

- 230 7. Beaussier M, Delbos A, Maurice-Szamburski A, Ecoffey C, Mercadal L. Perioperative  
231 use of intravenous lidocaine. *Drugs* 2018;78:1229-1246.
- 232 8. Foo I, Macfarlane AJR, Srivastava D, Bhaskar A, Barker H, Knaggs R, et al. The use of  
233 intravenous lidocaine for postoperative pain and recovery: international consensus  
234 statement on efficacy and safety. *Anaesthesia* 2021;76:238-250.
- 235 9. Estebe JP. Intravenous lidocaine. *Best Pract Res Clin Anaesthesiol* 2017;31:513-521.
- 236 10. Barrette LX, Harris J, De Ravin E, Balar E, Moreira AG, Rajasekaran K. Clinical  
237 practice guidelines for pain management after tonsillectomy: Systematic quality  
238 appraisal using the AGREE II instrument. *Int J Pediatr Otorhinolaryngol*  
239 2022;156:111091.
- 240 11. Ochs HR, Knüchel M, Abernethy DR, Greenblatt DJ. Dose-independent  
241 pharmacokinetics of intravenous lidocaine in humans. *J Clin Pharmacol* 1983;23:186-  
242 188.
- 243